4 reports

  • TARGET COMPANY INFORMATION COMPANY NAME
  • FINANCIAL ADVISOR

Rebellious genes are the ones that are working when/ where they should not e. g. in cancers, inflammatory conditions, Alzheimer' s and autoimmune diseases.

  • Cancer
  • Therapy
  • United Kingdom
  • ValiRx Plc
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018
  • Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development

In this trial, ## patients with PASI scores of ##. ## or greater will be randomized ##:##:##:## to receive weekly subcutaneous doses of IMO-## at ##. ##, ##. ##, or ##. ## mg/ kg/ week or placebo for ## weeks.

  • Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Idera Pharmaceuticals, Inc.
  • Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development
  • Toll Like Receptor 8 (CD288 or TLR8) - Dormant Products

In this trial, ## patients with PASI scores of ##. ## or greater will be randomized ##:##:##:## to receive weekly subcutaneous doses of IMO-## at ##. ##, ##. ##, or ##. ## mg/ kg/ week or placebo for ## weeks.

  • Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Idera Pharmaceuticals, Inc.
  • PRODUCT DESCRIPTION
  • DEAL RATIONALE

Summary ValiRx Plc (ValiRx) is a biopharmaceutical company that develops technologies and therapeutic options for the treatment of cancer.The company’s products and technology include GeneICE-silencing rebellious genes, GeneICE – BCL-2, VAL201-prostate cancer, NAV3 cancer screening test and VAL401-lung cancer. It...

  • Cancer
  • United Kingdom
  • Company
  • Deals & Alliance
  • ValiRx Plc